|
USA-NY-LATHAM Azienda Directories
|
Azienda News:
- FDA approves darolutamide for metastatic castration-sensitive . . .
On June 3, 2025, the Food and Drug Administration (FDA) approved darolutamide (Nubeqa, Bayer Healthcare Pharmaceuticals Inc ) for metastatic castration-sensitive prostate cancer (mCSPC)
- U. S. FDA Approves NUBEQA® (darolutamide) to Treat . . . - Bayer
WHIPPANY, N J , June 3, 2025 – Bayer announced today that the U S Food and Drug Administration (FDA) has approved its oral androgen receptor inhibitor (ARi) NUBEQA® (darolutamide) for the treatment of adult patients with metastatic castration-sensitive prostate cancer (mCSPC), which is also known as metastatic hormone-sensitive prostate cancer (mHSPC)
- Pfizer Provides Update on U. S. Regulatory Review of TALZENNA . . .
New York, June 13, 2025 – Pfizer Inc (NYSE: PFE) today announced the U S Food and Drug Administration’s (FDA) decision on the supplemental New Drug Application (sNDA) for TALZENNA® (talazoparib) in combination with XTANDI® (enzalutamide) for men with metastatic castration-resistant prostate cancer (mCRPC)
- Issue 12 - June 15, 2025 - pbdrx. com
On June 3, 2025, Nubeqa® (darolutamide) received an expanded indication from the U S Food and Drug Administration (FDA) for the treatment of adult patients with metastatic castration-sensitive prostate cancer (mCSPC), a type of advanced prostate cancer that has spread from the prostate into other parts of the body
- Darolutamide Now Approved as Single Agent for MCSPC - Medscape
The US Food and Drug Administration (FDA) has approved single-agent darolutamide (Nubeqa, Bayer Healthcare Pharmaceuticals, Inc ) for the treatment of metastatic castration–sensitive prostate
- New prostate cancer treatment options: Key physician . . .
Hormonal therapy is a first-line treatment for metastatic and advanced prostate cancer, often combined with other therapies to enhance its effectiveness By suppressing testosterone production, ADT slows cancer progression while alleviating symptoms
- Another Option for Metastatic Prostate Cancer | Cancer Today
DARRELL WILSON HAS RECEIVED nearly every type of available treatment for metastatic prostate cancer Since his diagnosis in 2009, the 74-year-old veteran and former banker, who lives in Boise, Idaho, has undergone chemotherapy, multiple types of hormone-deprivation therapy, immunotherapy and a kind of radiation called brachytherapy that uses tiny radioactive seeds implanted directly in the
|
|